A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT05733013
Status
Recruiting
Apply to this trial

Conditions

  • Refractory Thyroid Cancer
  • Thyroid
  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Surveillance Visit — OTHER
    Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.

Study Details

The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.

Key Dates

Start date
Feb 7, 2023
Status verified
Apr 2026
Primary completion
Feb 7, 2028
Completion
Feb 7, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Participants with refractory thyroid cancer patients

Primary Outcome Measure

Adverse events will be collected in every visit [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Laura Boucai, PhD
646-608-3906

Find similar trials in New York, NY

By research site
Memorial Sloan Kettering Cancer Center· New York, NY

Related Studies